CoChat
Sign Up
Cited by 724Ferroptosis and cancer prognosisIron Metabolism and DisordersNeurological diseases and metabolism

The DOI matches its Crossref record; 1,003 of the 1,003 references it cites were found in a registry or an index.

Iron homeostasis and ferroptosis in human diseases: mechanisms and therapeutic prospects

Open access
Ru, Qin, Li, Yusheng, Chen, Lin, Wu, Yuxiang, Min, Junxia, Wang, Fudi·2024·Signal Transduction and Targeted Therapy
DOI 10.1038/s41392-024-01969-zPMC PMC11486532
Open this paper in CoChat — free account

Abstract

Iron, an essential mineral in the body, is involved in numerous physiological processes, making the maintenance of iron homeostasis crucial for overall health. Both iron overload and deficiency can cause various disorders and human diseases. Ferroptosis, a form of cell death dependent on iron, is characterized by the extensive peroxidation of lipids. Unlike other kinds of classical unprogrammed cell death, ferroptosis is primarily linked to disruptions in iron metabolism, lipid peroxidation, and antioxidant system imbalance. Ferroptosis is regulated through transcription, translation, and post-translational modifications, which affect cellular sensitivity to ferroptosis. Over the past decade or so, numerous diseases have been linked to ferroptosis as part of their etiology, including cancers, metabolic disorders, autoimmune diseases, central nervous system diseases, cardiovascular diseases, and musculoskeletal diseases. Ferroptosis-related proteins have become attractive targets for many major human diseases that are currently incurable, and some ferroptosis regulators have shown therapeutic effects in clinical trials although further validation of their clinical potential is needed. Therefore, in-depth analysis of ferroptosis and its potential molecular mechanisms in human diseases may offer additional strategies for clinical prevention and treatment. In this review, we discuss the physiological significance of iron homeostasis in the body, the potential contribution of ferroptosis to the etiology and development of human diseases, along with the evidence supporting targeting ferroptosis as a therapeutic approach. Importantly, we evaluate recent potential therapeutic targets and promising interventions, providing guidance for future targeted treatment therapies against human diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41392-024-01969-z

Cites

1003 of 1003 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 The history and development of ferroptosis. In the figure, we outline the major events in the field of ferroptosis from 1955 to 2024, including the identification of the important role of cysteine in cell survival, the formal definition of ferroptosis, the discovery of system Xc−, oxytosis, PUFA-phospholipids (PUFA-PLs), and the proposal of antioxidant systems GPX4 and FSP1. This figure was created with BioRender (https://biorender.com/)
Fig. 1 The history and development of ferroptosis. In the figure, we outline the major events in the field of ferroptosis from 1955 to 2024, including the identification of the important role of cysteine in cell survival, the formal definition of ferroptosis, the discovery of system Xc−, oxytosis, PUFA-phospholipids (PUFA-PLs), and the proposal of antioxidant systems GPX4 and FSP1. This figure was created with BioRender (https://biorender.com/)CC BY · PubMed Central
Fig. 2 The crosstalk of ferroptosis with apoptosis, autophagy and pyroptosis. In the figure, we illustrate that ferritin produced in the ferroptosis can be digested and degraded by the autophagic mechanism, releasing excessive ferric ions that participate in the Fenton reaction, thereby inducing a vicious cycle of ferroptosis. Moreover, inflammasome NACHT, LRR and PYD domains-containing protein 3 (NLRP3), besides inducing pyroptosis, can promote ferroptosis by inhibiting GPX4. Excessive oxygen free radicals and lipid peroxidation products in the apoptosis signal pathway also induced ferroptosis. This figure was created with BioRender (https://biorender.com/)
Fig. 2 The crosstalk of ferroptosis with apoptosis, autophagy and pyroptosis. In the figure, we illustrate that ferritin produced in the ferroptosis can be digested and degraded by the autophagic mechanism, releasing excessive ferric ions that participate in the Fenton reaction, thereby inducing a vicious cycle of ferroptosis. Moreover, inflammasome NACHT, LRR and PYD domains-containing protein 3 (NLRP3), besides inducing pyroptosis, can promote ferroptosis by inhibiting GPX4. Excessive oxygen free radicals and lipid peroxidation products in the apoptosis signal pathway also induced ferroptosis. This figure was created with BioRender (https://biorender.com/)CC BY · PubMed Central
Fig. 3 The role of ferroptosis in human diseases. The figure illustrates that ferroptosis plays a significant role in many human diseases. In neurodegenerative conditions, it is involved in the pathological process of Alzheimer’s disease (AD), Parkinson’s disease (PD), and Huntington’s disease (HD), as well as in cerebral ischemia-reperfusion (I/R) injury, brain and spinal cord injury, and pain. In the circulatory system, ferroptosis contributes to heart failure, coronary heart disease, and myocardial I/R injury. In the musculoskeletal system, it leads to functional decline in skeletal muscle, bones, and joints. In chronic metabolic diseases, ferroptosis can trigger the occurrence and development of diabetes mellitus, hyperlipidemia, fatty liver disease, and obesity. In cancer, ferroptosis mainly affects tumor growth, metastasis, invasion, and chemoresistance. In autoimmune diseases, it is mainly involved in the pathogenesis of rheumatoid arthritis, systemic lupus erythematosus, and myasthenia gravis. In genetic diseases, ferroptosis predominantly affects thalassemia and progressive muscular dystrophy. This figure was created with BioRender (https://biorender.com/)
Fig. 3 The role of ferroptosis in human diseases. The figure illustrates that ferroptosis plays a significant role in many human diseases. In neurodegenerative conditions, it is involved in the pathological process of Alzheimer’s disease (AD), Parkinson’s disease (PD), and Huntington’s disease (HD), as well as in cerebral ischemia-reperfusion (I/R) injury, brain and spinal cord injury, and pain. In the circulatory system, ferroptosis contributes to heart failure, coronary heart disease, and myocardial I/R injury. In the musculoskeletal system, it leads to functional decline in skeletal muscle, bones, and joints. In chronic metabolic diseases, ferroptosis can trigger the occurrence and development of diabetes mellitus, hyperlipidemia, fatty liver disease, and obesity. In cancer, ferroptosis mainly affects tumor growth, metastasis, invasion, and chemoresistance. In autoimmune diseases, it is mainly involved in the pathogenesis of rheumatoid arthritis, systemic lupus erythematosus, and myasthenia gravis. In genetic diseases, ferroptosis predominantly affects thalassemia and progressive muscular dystrophy. This figure was created with BioRender (https://biorender.com/)CC BY · PubMed Central
Fig. 4 Ferroptosis in cardiovascular diseases. In the circulatory system, iron overload, lipid peroxidation and oxidative stress associated with ferroptosis can gradually induce coronary atherosclerotic heart disease and myocardial infarction (a), dilated cardiomyopathy (b), hypertrophic cardiomyopathy (c), and inflammatory infiltration of myocardium (d). This occurs through the damage of vascular endothelial cells and myocardial cells, leading to inflammatory responses. This figure was created with BioRender (https://biorender.com/)
Fig. 4 Ferroptosis in cardiovascular diseases. In the circulatory system, iron overload, lipid peroxidation and oxidative stress associated with ferroptosis can gradually induce coronary atherosclerotic heart disease and myocardial infarction (a), dilated cardiomyopathy (b), hypertrophic cardiomyopathy (c), and inflammatory infiltration of myocardium (d). This occurs through the damage of vascular endothelial cells and myocardial cells, leading to inflammatory responses. This figure was created with BioRender (https://biorender.com/)CC BY · PubMed Central
Fig. 5 Ferroptosis in neurodegenerative diseases. In the nervous system, ferroptosis primarily induces and promotes neuronal damage and axonal degeneration. It also facilitates the aggregation of amyloid-beta (Aβ) in the brain and contributes to the formation of neurofibrillary tangles. Additionally, ferroptosis activates glial cells, triggering an inflammatory response. These complex pathological changes in the brain interact with each other, leading to neurodegenerative diseases such as Alzheimer’s disease (AD), Parkinson’s disease (PD), and Huntington’s disease (HD), as well as ischemia-reperfusion injury and inflammatory responses. This figure was created with BioRender (https://biorender.com/)
Fig. 5 Ferroptosis in neurodegenerative diseases. In the nervous system, ferroptosis primarily induces and promotes neuronal damage and axonal degeneration. It also facilitates the aggregation of amyloid-beta (Aβ) in the brain and contributes to the formation of neurofibrillary tangles. Additionally, ferroptosis activates glial cells, triggering an inflammatory response. These complex pathological changes in the brain interact with each other, leading to neurodegenerative diseases such as Alzheimer’s disease (AD), Parkinson’s disease (PD), and Huntington’s disease (HD), as well as ischemia-reperfusion injury and inflammatory responses. This figure was created with BioRender (https://biorender.com/)CC BY · PubMed Central
Fig. 6 Ferroptosis in musculoskeletal diseases. Ferroptosis in the musculoskeletal system contributes to the occurrence and development of arthritis primarily through lipid peroxidation and oxidative stress, which to damage the joint synovial membrane, matrix, and hyperactivated immune cells. Additionally, ferroptosis disrupts the delicate balance of osteoblasts and osteoclasts in the bone tissue, leading to the development of osteoporosis. Ferroptosis also plays a crucial role in the decline of quality and function in skeletal muscle, cardiac muscle and smooth muscle, there by inducing the onset of sarcopenia. This figure was created with BioRender (https://biorender.com/)
Fig. 6 Ferroptosis in musculoskeletal diseases. Ferroptosis in the musculoskeletal system contributes to the occurrence and development of arthritis primarily through lipid peroxidation and oxidative stress, which to damage the joint synovial membrane, matrix, and hyperactivated immune cells. Additionally, ferroptosis disrupts the delicate balance of osteoblasts and osteoclasts in the bone tissue, leading to the development of osteoporosis. Ferroptosis also plays a crucial role in the decline of quality and function in skeletal muscle, cardiac muscle and smooth muscle, there by inducing the onset of sarcopenia. This figure was created with BioRender (https://biorender.com/)CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 1,003 references

Research works printed but not linked: 1

  1. Heit, B. S. et al. Tonic extracellular glutamate and ischaemia. glutamate antiporter Syst. x(c.) (-) regulates anoxic depolarization hippocampus. J. Physiol. 601, 607–629 (2023).

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Ru, Q., Li, Y., Chen, L., Wu, Y., Min, J., & Wang, F.
Affiliations
  • Jianghan University (CN)
  • Central South University (CN)
  • First Affiliated Hospital Zhejiang University (CN)
  • Zhejiang University (CN)
Corresponding author
  • Min, Junxia
  • Wang, Fudi
ORCID
Venue
Signal Transduction and Targeted Therapy
Publisher
Springer Science and Business Media LLC
Published
2024-10-14
Volume
9
Issue
1
Pages
271-271
ISSN
2059-3635 (ISSN-L)
DOI
10.1038/s41392-024-01969-z
PMC
PMC11486532
OpenAlex
W4403369705
Cited by
724
References
1,003
Citations by year
2026: 407 · 2025: 310 · 2024: 7
FWCI
53.50
Type
journal article
Language
en
Open access
Licence
Locations
  • Signal Transduction and Targeted Therapy (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • National Natural Science Foundation of China (32330047, 82072506, 82071970, 31970689)
  • Natural Science Foundation of Hubei Province (2024AFB971)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
  • Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
  • Life Sciences › Neuroscience › Neurology › Neurological diseases and metabolism
Keywords
iron homeostasis, ferroptosis, iron overload, iron deficiency, lipid peroxidation, antioxidant imbalance, ferroptosis regulators, cancer, metabolic disorders, autoimmune disease, central nervous system disorders, cardiovascular disease, musculoskeletal disorders, ferroptosis-targeted therapy
MeSH terms
Ferroptosis, Autoimmune Diseases, Cardiovascular Diseases, Homeostasis, Humans, Iron, Metabolic Diseases, Neoplasms, Lipid Peroxidation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review